Benitec Biopharma(US:BNTC) Globenewswireยท2025-09-22 20:05Core Insights - Benitec Biopharma Inc. is advancing its BB-301 clinical development program for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and expects to provide interim clinical study results for Cohort 1 in Q4 2025 [1][4][2] Corporate Highlights - The Independent Data Safety Monitoring Board (DSMB) recommended the continuation of subject enrollment into the BB-301 Phase 1b/2a Treatment Study after the safe treatment of the sixth subject in Cohort 1, with enrollment for Cohort 2 expected to begin in Q4 2025 [3][2] Financial Highlights - For the year ended June 30, 2025, total expenses were $41.8 million, up from $22.5 million in 2024, with research and development expenses increasing to $18.3 million from $15.6 million [5][6] - General and administrative expenses rose to $23.4 million in 2025 from $7.0 million in 2024, primarily due to higher share-based compensation and increased legal and consulting fees [6] - The net loss attributable to shareholders for the year was $37.9 million, or $1.05 per share, compared to a net loss of $22.4 million, or $1.22 per share, in the previous year [7][10] Balance Sheet Overview - As of June 30, 2025, the company had cash and cash equivalents of $97.7 million, an increase from $50.9 million in 2024 [9] - Total assets were reported at $99.6 million, compared to $52.2 million in the previous year, indicating significant growth in the company's financial position [9] About BB-301 - BB-301 utilizes a modified AAV9 capsid to promote co-expression of a functional version of the PABPN1 protein while silencing the expression of the faulty mutant PABPN1 gene, positioning it as a potential therapy for OPMD [11] About Benitec Biopharma, Inc. - Benitec Biopharma is a clinical-stage biotechnology company focused on developing novel genetic medicines, particularly for chronic and life-threatening conditions like OPMD, using its proprietary "Silence and Replace" platform [12]